EMERYVILLE, Calif., Nov. 9, 2017 /PRNewswire/ -- Nanomix, Inc., a developer of next-generation, mobile, point-of-care
The agreements include an approximately $9M in private equity financing that includes both new and existing Nanomix investors, $6M in milestone-based license fees related to the collaborations, and significant future royalties on sales of human and veterinary diagnostic products.
"As part of our integrated healthcare business strategy, we are investing in these advanced healthcare products and technologies to help meet the demand for high quality, precise, immediate and available healthcare diagnosis at an affordable cost for all people in the China and Asia sphere," said Conroy Cheng, Director of World Technology East and RedPharm Biotechnology Ltd. "The Nanomix technology and allied products will deliver critical advanced diagnostic tools and information for multiple markets."
"This significant partnership and financing enables Nanomix to accelerate its business strategy and expand the company's horizons through our new relationship with Conroy and his team. Their vision and reach in China and throughout Asia will be key to establishing Nanomix as a worldwide leader in point-of-care diagnostics," said Garrett Gruener, Executive Chairman of Nanomix.
"Nanomix mobile diagnostic technology and products meet the demanding needs of critical care diagnostics in hospital and non-hospital situations. Prompt and accurate diagnostic information when time matters, will significantly improve clinical decision making and improve patient outcomes," said David Ludvigson, President and Chief Executive Officer of Nanomix. "Our initial diagnostic work in sepsis will be complemented by future developments in cardiac care, brain injury and other time-critical medical conditions."
About RedPharm Biotechnology Ltd. and US affiliated Medical Technology Associates II Alliance:RedPharm (Beijing) Biotechnology Co., Ltd. (RedPharm) was founded in 2016, focusing on research and development (R&D) and production of bio-medical products as well as new therapeutic biologics for various difficult diseases that endanger humans and animals. RBL-BJ will continue to focus on innovation and R&D in the fields of 'Biopharmaceuticals,' 'POCT immediate diagnosis,' 'ARIA retinal scan,' and 'CRO services.'
RedPharm for the Asia market has an interdisciplinary R&D team and continues to integrate resources and build partnerships with well-known institutions both in and out of China, thus adding to the company's R&D ability and accelerating the progress of technology transformation. Its US affiliate, Medical Technology Associates II is both co-developer and US-based regulatory arm for all collaborative technology and products. The company has access to China's world class technology research centers and is constructing a manufacturing facility in compliance with US Food and Drug Administration and European standards located in the 'Sino-German United Group' (Qingdao) advanced technology center. http://www.redpharm.com
About NanomixNanomix has developed the next generation of mobile, point of care medical diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings. Rapid, lab quality diagnostic information in a mobile, connected system will improve patient care and outcomes in time critical and remote care situations. For more information, please visit our website at http://www.nano.com.
David LudvigsonPresident & CEOdludvigson (at) nano.com Ph: 1-510-428-5332
Joan KureczkaKureczka/Martin AssociatesJoan (at) kureczka-martin.comPh: 1-415-821-2413
View original content:http://www.prnewswire.com/news-releases/nanomix-announces-equity-financing-and-collaboration-with-hong-kong-beijing-based-world-technology-east-and-redpharm-biotechnology-companies-300552518.html
SOURCE Nanomix, Inc.
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All